Impact of blood-based biomarkers on Alzheimer’s disease treatments



Published
Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, Amsterdam, The Netherlands, discusses how blood-based biomarkers can help develop treatments for Alzheimer’s disease patients. Indeed, they provide information quickly on whether a treatment is working, which shortens the duration of the trial. This reduces cost and helps the inclusion of patients within a clinical trial. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases hosted in Barcelona, Spain.
Category
Health
Be the first to comment